

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re application of:	Examiner: Seharaseyon, Jegatheesan
Madaline CHIRICA, <i>et al.</i>	Art Unit: 1647
Application No.: 10/720,026	Conf. No.: 3154
Filed: November 21, 2003	
For: MAMMALIAN RECEPTOR PROTEINS; RELATED REAGENTS AND METHODS	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This is a response to the Restriction Requirement dated September 26, 2006. A petition for a one-month extension of time, thereby extending the time to reply from October 26, 2006, to November 26, 2006, accompanies this response.

I. Restriction Requirement

The Examiner restricted the application into 10 separate inventions:

- I. Claims 1 (in part), 2-4, 5 (in part), 6, 8 and 9, drawn to a method of treating a human subject experiencing a physiological disorder comprising administering an effective amount of an antagonist of DCRS5, classified in class 514, subclass 12.
- II. Claims 1 (in part), 2-4, 7 (in part) and 8, drawn to a method of treating a human subject experiencing a physiological disorder comprising administering an effective amount of an agonist of DCRS5, classified in class 514, subclass 12.
- III. Claims 1 (in part), 2-4, 5 (in part), 5, 8 and 9, drawn to a method of treating a human subject experiencing a physiological disorder comprising administering an effective amount of an antagonist of P19, classified in class 514, subclass 12.

- IV. Claims 1 (in part), 2-4, 7 (in part) and 8, drawn to a method of treating a human subject experiencing a physiological disorder comprising administering an effective amount of an agonist P19, classified in class 514, subclass 12.
- V. Claims 10-17, drawn to a method of diagnosing a physiological disorder contacting a binding composition that specifically binds to DCRS5, wherein composition contains an antibody, classified in class 436, subclass 501.
- VI. Claims 10-17, drawn to a method of diagnosing a physiological disorder contacting a binding composition that specifically binds to DCRS5, wherein composition contains an antibody, classified in class 436, subclass 501.
- VII. Claims 10-17, drawn to a method of diagnosing a physiological disorder contacting a binding composition that specifically binds to p19, wherein composition contains an antibody, classified in class 436, subclass 501.
- VIII. Claims 10-17, drawn to a method of diagnosing a physiological disorder contacting a binding composition that specifically binds to p19, wherein composition contains a nucleic acid, classified in class 435, subclass 6.
- IX. Claims 10-17, drawn to a method of diagnosing a physiological disorder contacting a binding composition that specifically binds to p19, wherein composition contains a detectable label, classification unknown.
- X. Claims 10-17, drawn to a method of diagnosing a physiological disorder contacting a binding composition that specifically binds to p19, wherein composition contains a detectable label, classification unknown.

Applicants provisionally elect Group 1, with Claims 1 (in part), 2-4, 5 (in part), 6, 8 and 9, drawn to a method of treating a human subject experiencing a physiological disorder comprising administering an effective amount of an antagonist of DCRS5, classified in class 514, subclass 12, for example, as discussed in the Office Action.

Applicants further elect species inflammatory bowel disorder.

Applicants further elect SEQ ID NO: 2.

Applicants will address the issue of inventorship for the elected claims and amend inventorship appropriately if the elected restriction is made final.

Applicants reserve the right to file subsequent applications claiming the non-elected subject matter and do not waive any of their rights or abandon any non-elected


subject matter. Since Applicants have fully and completely responded to the Restriction Requirement and have made the required election, this application is now in order for early action.

If the Examiner believes that a telephone conference would aid the prosecution of this case in any way, please call the undersigned.

Applicant believes that no additional fees are due with this communication. Should this not be the case, the Commissioner is hereby authorized to debit any charges or refund any overpayments to DNAX Deposit Account No. 04-1239.

Respectfully submitted,

Date: November 22, 2006

By: 
Gregory Bellomy,
Reg. No. 48,451
Attorney for Applicants

Customer No. 028008

DNAX Research, Inc.
901 California Avenue
Palo Alto, CA 94304-1104
Telephone (Switchboard): (650) 496-6400
Telephone No. (Direct): (650) 496-6565
Facsimile No.: (650) 496-1200